Beijing Dongfang Biotech Co., Ltd.
6 clinical trials · Sponsor
◉ Watch Beijing Dongfang Biotech Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin (NCT06257966) | Beijing Dongfang Biotech Co., Ltd. | 2024-07-17 |
| A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients (NCT06254014) | Beijing Dongfang Biotech Co., Ltd. | 2024-07-10 |
| Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects (NCT06247748) | Beijing Dongfang Biotech Co., Ltd. | 2023-10-19 |
| JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety (NCT04874844) | Beijing Dongfang Biotech Co., Ltd. | 2021-07-30 |
| Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09 (NCT04354090) | Beijing Dongfang Biotech Co., Ltd. | 2018-04-26 |
| a Study of JY09 in Chinese Healthy Subjects (NCT02971722) | Beijing Dongfang Biotech Co., Ltd. | 2016-12-01 |
Track Beijing Dongfang Biotech Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.